Lupin Limited, a global pharmaceutical leader, has received tentative approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Amifampridine Tablets, 10 mg. This approval allows Lupin to introduce a bioequivalent alternative to Firdapse® (10 mg) by Catalyst Pharmaceuticals, Inc.